TY  - JOUR
AU  - Đukić, Ivana
AU  - Kaličanin, Nevena
AU  - Senćanski, Milan V.
AU  - Pajović, Snežana B.
AU  - Milićević, Jelena S.
AU  - Prljić, Jelena
AU  - Paessler, Slobodan
AU  - Prodanović, Radivoje
AU  - Glišić, Sanja
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10629
AB  - Drug resistance is a critical problem in health care that affects therapy outcomes and requires new approaches to drugdesign. SARS-CoV-2 Mpro mutations are of concern as they can potentially reduce therapeutic efficacy. Viral infections are amongst themany disorders for which nutraceuticals have been employed as an adjunct therapy. The aim of this study was to examine the potentialin vitro activity of L-arginine and vitamin C against SARS-CoV-2 Mpro. Methods: The Mpro inhibition assay was developed by cloning,expression, purification, and characterization of Mpro. Selected compounds were then screened for protease inhibition. Results: Largininewas found to be active against SARS-CoV-2 Mpro, while a vitamin C/L-arginine combination had a synergistic antiviral actionagainst Mpro. These findings confirm the results of our previous in silico repurposing study that showed L-arginine and vitamin C werepotential Mpro inhibitors. Moreover, they suggest a possible molecular mechanism to explain the beneficial effect of arginine in COVIDpatients. Conclusions: The findings of the current study are important because they help to identify COVID-19 treatments that areefficient, inexpensive, and have a favorable safety profile. The results of this study also suggest a possible adjuvant nutritional strategyfor COVID-19 that could be used in conjunction with pharmacological agents.
T2  - Frontiers in Bioscience - Landmark
T1  - Inhibition of SARS-CoV-2 Mpro with Vitamin C, L-Arginine and a Vitamin C/L-Arginine Combination
VL  - 28
IS  - 1
SP  - 8
DO  - 10.31083/j.fbl2801008
ER  - 

@article{
author = "Đukić, Ivana and Kaličanin, Nevena and Senćanski, Milan V. and Pajović, Snežana B. and Milićević, Jelena S. and Prljić, Jelena and Paessler, Slobodan and Prodanović, Radivoje and Glišić, Sanja",
year = "2023",
abstract = "Drug resistance is a critical problem in health care that affects therapy outcomes and requires new approaches to drugdesign. SARS-CoV-2 Mpro mutations are of concern as they can potentially reduce therapeutic efficacy. Viral infections are amongst themany disorders for which nutraceuticals have been employed as an adjunct therapy. The aim of this study was to examine the potentialin vitro activity of L-arginine and vitamin C against SARS-CoV-2 Mpro. Methods: The Mpro inhibition assay was developed by cloning,expression, purification, and characterization of Mpro. Selected compounds were then screened for protease inhibition. Results: Largininewas found to be active against SARS-CoV-2 Mpro, while a vitamin C/L-arginine combination had a synergistic antiviral actionagainst Mpro. These findings confirm the results of our previous in silico repurposing study that showed L-arginine and vitamin C werepotential Mpro inhibitors. Moreover, they suggest a possible molecular mechanism to explain the beneficial effect of arginine in COVIDpatients. Conclusions: The findings of the current study are important because they help to identify COVID-19 treatments that areefficient, inexpensive, and have a favorable safety profile. The results of this study also suggest a possible adjuvant nutritional strategyfor COVID-19 that could be used in conjunction with pharmacological agents.",
journal = "Frontiers in Bioscience - Landmark",
title = "Inhibition of SARS-CoV-2 Mpro with Vitamin C, L-Arginine and a Vitamin C/L-Arginine Combination",
volume = "28",
number = "1",
pages = "8",
doi = "10.31083/j.fbl2801008"
}

Đukić, I., Kaličanin, N., Senćanski, M. V., Pajović, S. B., Milićević, J. S., Prljić, J., Paessler, S., Prodanović, R.,& Glišić, S.. (2023). Inhibition of SARS-CoV-2 Mpro with Vitamin C, L-Arginine and a Vitamin C/L-Arginine Combination. in Frontiers in Bioscience - Landmark, 28(1), 8.
https://doi.org/10.31083/j.fbl2801008

Đukić I, Kaličanin N, Senćanski MV, Pajović SB, Milićević JS, Prljić J, Paessler S, Prodanović R, Glišić S. Inhibition of SARS-CoV-2 Mpro with Vitamin C, L-Arginine and a Vitamin C/L-Arginine Combination. in Frontiers in Bioscience - Landmark. 2023;28(1):8.
doi:10.31083/j.fbl2801008 .

Đukić, Ivana, Kaličanin, Nevena, Senćanski, Milan V., Pajović, Snežana B., Milićević, Jelena S., Prljić, Jelena, Paessler, Slobodan, Prodanović, Radivoje, Glišić, Sanja, "Inhibition of SARS-CoV-2 Mpro with Vitamin C, L-Arginine and a Vitamin C/L-Arginine Combination" in Frontiers in Bioscience - Landmark, 28, no. 1 (2023):8,
https://doi.org/10.31083/j.fbl2801008 . .

TY  - JOUR
AU  - Radošević, Draginja
AU  - Senćanski, Milan V.
AU  - Perović, Vladimir R.
AU  - Veljković, Nevena V.
AU  - Prljić, Jelena
AU  - Veljković, Veljko
AU  - Mantlo, Emily
AU  - Bukreyeva, Natalya
AU  - Paessler, Slobodan
AU  - Glišić, Sanja
PY  - 2019
UR  - https://www.frontiersin.org/article/10.3389/fcimb.2019.00067/full
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8163
AB  - Influenza A virus (IAV) matrix protein 2 (M2), an ion channel, is crucial for virus infection, and therefore, an important anti-influenza drug target. Adamantanes, also known as M2 channel blockers, are one of the two classes of Food and Drug Administration-approved anti-influenza drugs, although their use was discontinued due to prevalent drug resistance. Fast emergence of resistance to current anti-influenza drugs have raised an urgent need for developing new anti-influenza drugs against resistant forms of circulating viruses. Here we propose a simple theoretical criterion for fast virtual screening of molecular libraries for candidate anti-influenza ion channel inhibitors both for wild type and adamantane-resistant influenza A viruses. After in silico screening of drug space using the EIIP/AQVN filter and further filtering of drugs by ligand based virtual screening and molecular docking we propose the best candidate drugs as potential dual inhibitors of wild type and adamantane-resistant influenza A viruses. Finally, guanethidine, the best ranked drug selected from ligand-based virtual screening, was experimentally tested. The experimental results show measurable anti-influenza activity of guanethidine in cell culture. © 2019 Radosevic, Sencanski, Perovic, Veljkovic, Prljic, Veljkovic, Mantlo, Bukreyeva, Paessler and Glisic.
T2  - Frontiers in Cellular and Infection Microbiology
T1  - Virtual Screen for Repurposing of Drugs for Candidate Influenza a M2 Ion-Channel Inhibitors
VL  - 9
SP  - 67
DO  - 10.3389/fcimb.2019.00067
ER  - 

@article{
author = "Radošević, Draginja and Senćanski, Milan V. and Perović, Vladimir R. and Veljković, Nevena V. and Prljić, Jelena and Veljković, Veljko and Mantlo, Emily and Bukreyeva, Natalya and Paessler, Slobodan and Glišić, Sanja",
year = "2019",
abstract = "Influenza A virus (IAV) matrix protein 2 (M2), an ion channel, is crucial for virus infection, and therefore, an important anti-influenza drug target. Adamantanes, also known as M2 channel blockers, are one of the two classes of Food and Drug Administration-approved anti-influenza drugs, although their use was discontinued due to prevalent drug resistance. Fast emergence of resistance to current anti-influenza drugs have raised an urgent need for developing new anti-influenza drugs against resistant forms of circulating viruses. Here we propose a simple theoretical criterion for fast virtual screening of molecular libraries for candidate anti-influenza ion channel inhibitors both for wild type and adamantane-resistant influenza A viruses. After in silico screening of drug space using the EIIP/AQVN filter and further filtering of drugs by ligand based virtual screening and molecular docking we propose the best candidate drugs as potential dual inhibitors of wild type and adamantane-resistant influenza A viruses. Finally, guanethidine, the best ranked drug selected from ligand-based virtual screening, was experimentally tested. The experimental results show measurable anti-influenza activity of guanethidine in cell culture. © 2019 Radosevic, Sencanski, Perovic, Veljkovic, Prljic, Veljkovic, Mantlo, Bukreyeva, Paessler and Glisic.",
journal = "Frontiers in Cellular and Infection Microbiology",
title = "Virtual Screen for Repurposing of Drugs for Candidate Influenza a M2 Ion-Channel Inhibitors",
volume = "9",
pages = "67",
doi = "10.3389/fcimb.2019.00067"
}

Radošević, D., Senćanski, M. V., Perović, V. R., Veljković, N. V., Prljić, J., Veljković, V., Mantlo, E., Bukreyeva, N., Paessler, S.,& Glišić, S.. (2019). Virtual Screen for Repurposing of Drugs for Candidate Influenza a M2 Ion-Channel Inhibitors. in Frontiers in Cellular and Infection Microbiology, 9, 67.
https://doi.org/10.3389/fcimb.2019.00067

Radošević D, Senćanski MV, Perović VR, Veljković NV, Prljić J, Veljković V, Mantlo E, Bukreyeva N, Paessler S, Glišić S. Virtual Screen for Repurposing of Drugs for Candidate Influenza a M2 Ion-Channel Inhibitors. in Frontiers in Cellular and Infection Microbiology. 2019;9:67.
doi:10.3389/fcimb.2019.00067 .

Radošević, Draginja, Senćanski, Milan V., Perović, Vladimir R., Veljković, Nevena V., Prljić, Jelena, Veljković, Veljko, Mantlo, Emily, Bukreyeva, Natalya, Paessler, Slobodan, Glišić, Sanja, "Virtual Screen for Repurposing of Drugs for Candidate Influenza a M2 Ion-Channel Inhibitors" in Frontiers in Cellular and Infection Microbiology, 9 (2019):67,
https://doi.org/10.3389/fcimb.2019.00067 . .

TY  - JOUR
AU  - Glišić, Sanja
AU  - Paessler, Slobodan
AU  - Veljković, Nevena V.
AU  - Perović, Vladimir R.
AU  - Prljić, Jelena
AU  - Veljković, Veljko
PY  - 2015
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/709
AB  - Introduction: The Ebola 2014/2015 outbreak has had devastating effects on the people living in West Africa. The spread of the disease in endemic countries and the potential introduction of sporadic cases in other continents points out the global health threat of Ebola virus disease (EVD). Despite the urgent need for treating EVD, there are no approved treatments. Given the lack of treatments available, alternative therapeutic strategies have had to be used. Areas covered: This article summarizes the unregistered therapeutics that were used to treat patients during the Ebola 2014/2015 outbreak, in addition to approaches used for the selection of candidate drugs. The article also proposes potential theoretical criterion for use in virtual screening of molecular libraries for candidate Ebola drugs. Expert opinion: In the absence of approved therapeutics for EVD, experimental drugs have had to be used. The repurposing of approved drugs for the treatment of EVD, as an alternative therapeutic strategy, has also been suggested. Screening in vitro- and in sllico-approved drugs revealed several promising candidates but further testing is required to test their efficacy. All these therapeutic approaches are, however, only short-term solutions and there is still an urgent need for the development of specific drugs for the current and future outbreaks.
T2  - Expert Opinion on Drug Discovery
T1  - Improving attrition rates in Ebola virus drug discovery
VL  - 10
IS  - 9
SP  - 1025
EP  - 1032
DO  - 10.1517/17460441.2015.1062872
ER  - 

@article{
author = "Glišić, Sanja and Paessler, Slobodan and Veljković, Nevena V. and Perović, Vladimir R. and Prljić, Jelena and Veljković, Veljko",
year = "2015",
abstract = "Introduction: The Ebola 2014/2015 outbreak has had devastating effects on the people living in West Africa. The spread of the disease in endemic countries and the potential introduction of sporadic cases in other continents points out the global health threat of Ebola virus disease (EVD). Despite the urgent need for treating EVD, there are no approved treatments. Given the lack of treatments available, alternative therapeutic strategies have had to be used. Areas covered: This article summarizes the unregistered therapeutics that were used to treat patients during the Ebola 2014/2015 outbreak, in addition to approaches used for the selection of candidate drugs. The article also proposes potential theoretical criterion for use in virtual screening of molecular libraries for candidate Ebola drugs. Expert opinion: In the absence of approved therapeutics for EVD, experimental drugs have had to be used. The repurposing of approved drugs for the treatment of EVD, as an alternative therapeutic strategy, has also been suggested. Screening in vitro- and in sllico-approved drugs revealed several promising candidates but further testing is required to test their efficacy. All these therapeutic approaches are, however, only short-term solutions and there is still an urgent need for the development of specific drugs for the current and future outbreaks.",
journal = "Expert Opinion on Drug Discovery",
title = "Improving attrition rates in Ebola virus drug discovery",
volume = "10",
number = "9",
pages = "1025-1032",
doi = "10.1517/17460441.2015.1062872"
}

Glišić, S., Paessler, S., Veljković, N. V., Perović, V. R., Prljić, J.,& Veljković, V.. (2015). Improving attrition rates in Ebola virus drug discovery. in Expert Opinion on Drug Discovery, 10(9), 1025-1032.
https://doi.org/10.1517/17460441.2015.1062872

Glišić S, Paessler S, Veljković NV, Perović VR, Prljić J, Veljković V. Improving attrition rates in Ebola virus drug discovery. in Expert Opinion on Drug Discovery. 2015;10(9):1025-1032.
doi:10.1517/17460441.2015.1062872 .

Glišić, Sanja, Paessler, Slobodan, Veljković, Nevena V., Perović, Vladimir R., Prljić, Jelena, Veljković, Veljko, "Improving attrition rates in Ebola virus drug discovery" in Expert Opinion on Drug Discovery, 10, no. 9 (2015):1025-1032,
https://doi.org/10.1517/17460441.2015.1062872 . .

TY  - JOUR
AU  - Veljković, Veljko
AU  - Paessler, Slobodan
AU  - Glišić, Sanja
AU  - Prljić, Jelena
AU  - Perović, Vladimir R.
AU  - Veljković, Nevena V.
AU  - Scotch, Matthew
PY  - 2015
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/863
AB  - A key factor in the effectiveness of the seasonal influenza vaccine is its immunological compatibility with the circulating viruses during the season. Here we propose a new bioinformatics approach for analysis of influenza viruses which could be used as an efficient tool for selection of vaccine viruses, assessment of the effectiveness of seasonal influenza vaccines, and prediction of the epidemic/pandemic potential of novel influenza viruses.
T2  - Frontiers in Microbiology
T1  - Evolution of 2014/15 H3N2 Influenza Viruses Circulating in US: Consequences for Vaccine Effectiveness and Possible New Pandemic
VL  - 6
DO  - 10.3389/fmicb.2015.01456
ER  - 

@article{
author = "Veljković, Veljko and Paessler, Slobodan and Glišić, Sanja and Prljić, Jelena and Perović, Vladimir R. and Veljković, Nevena V. and Scotch, Matthew",
year = "2015",
abstract = "A key factor in the effectiveness of the seasonal influenza vaccine is its immunological compatibility with the circulating viruses during the season. Here we propose a new bioinformatics approach for analysis of influenza viruses which could be used as an efficient tool for selection of vaccine viruses, assessment of the effectiveness of seasonal influenza vaccines, and prediction of the epidemic/pandemic potential of novel influenza viruses.",
journal = "Frontiers in Microbiology",
title = "Evolution of 2014/15 H3N2 Influenza Viruses Circulating in US: Consequences for Vaccine Effectiveness and Possible New Pandemic",
volume = "6",
doi = "10.3389/fmicb.2015.01456"
}

Veljković, V., Paessler, S., Glišić, S., Prljić, J., Perović, V. R., Veljković, N. V.,& Scotch, M.. (2015). Evolution of 2014/15 H3N2 Influenza Viruses Circulating in US: Consequences for Vaccine Effectiveness and Possible New Pandemic. in Frontiers in Microbiology, 6.
https://doi.org/10.3389/fmicb.2015.01456

Veljković V, Paessler S, Glišić S, Prljić J, Perović VR, Veljković NV, Scotch M. Evolution of 2014/15 H3N2 Influenza Viruses Circulating in US: Consequences for Vaccine Effectiveness and Possible New Pandemic. in Frontiers in Microbiology. 2015;6.
doi:10.3389/fmicb.2015.01456 .

Veljković, Veljko, Paessler, Slobodan, Glišić, Sanja, Prljić, Jelena, Perović, Vladimir R., Veljković, Nevena V., Scotch, Matthew, "Evolution of 2014/15 H3N2 Influenza Viruses Circulating in US: Consequences for Vaccine Effectiveness and Possible New Pandemic" in Frontiers in Microbiology, 6 (2015),
https://doi.org/10.3389/fmicb.2015.01456 . .

TY  - JOUR
AU  - Maga, Giovanni
AU  - Veljković, Nevena V.
AU  - Crespan, Emmanuele
AU  - Spadari, Silvio
AU  - Prljić, Jelena
AU  - Perović, Vladimir R.
AU  - Glišić, Sanja
AU  - Veljković, Veljko
PY  - 2013
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/5227
AB  - Introduction: Recently, the new concept of the long-range intermolecular interactions in biological systems has been proposed. Combined use of molecular modeling techniques and the screening techniques based on the long-range interaction concept could significantly improve and accelerate discovery of new HIV drugs. However, any hit identified in silico needs to be characterized with respect to its biological target by enzymatic studies. Combined use of the in silico screening and the enzymatic studies allows an efficient selection of new anti-HIV drugs. Areas covered: The focus of this article is on the in silico screening of molecular libraries for candidate new HIV drugs, which is based on the molecular descriptors determining the long-range interaction between the drugs and their therapeutic target. This article also reviews the techniques for enzyme kinetic studies which are required for optimization of in silico selected candidate anti-HIV drugs. Expert opinion: The novel approach of combining in silico screening techniques with enzymatic studies enables the accurate measurement of the quantitative descriptors of ligand-enzyme interactions. This novel method is a powerful tool for new anti-HIV drug discovery which can also reduce the drug development costs.
T2  - Expert Opinion on Drug Discovery
T1  - New in silico and conventional in vitro approaches to advance HIV drug discovery and design
VL  - 8
IS  - 1
SP  - 83
EP  - 92
DO  - 10.1517/17460441.2013.741118
ER  - 

@article{
author = "Maga, Giovanni and Veljković, Nevena V. and Crespan, Emmanuele and Spadari, Silvio and Prljić, Jelena and Perović, Vladimir R. and Glišić, Sanja and Veljković, Veljko",
year = "2013",
abstract = "Introduction: Recently, the new concept of the long-range intermolecular interactions in biological systems has been proposed. Combined use of molecular modeling techniques and the screening techniques based on the long-range interaction concept could significantly improve and accelerate discovery of new HIV drugs. However, any hit identified in silico needs to be characterized with respect to its biological target by enzymatic studies. Combined use of the in silico screening and the enzymatic studies allows an efficient selection of new anti-HIV drugs. Areas covered: The focus of this article is on the in silico screening of molecular libraries for candidate new HIV drugs, which is based on the molecular descriptors determining the long-range interaction between the drugs and their therapeutic target. This article also reviews the techniques for enzyme kinetic studies which are required for optimization of in silico selected candidate anti-HIV drugs. Expert opinion: The novel approach of combining in silico screening techniques with enzymatic studies enables the accurate measurement of the quantitative descriptors of ligand-enzyme interactions. This novel method is a powerful tool for new anti-HIV drug discovery which can also reduce the drug development costs.",
journal = "Expert Opinion on Drug Discovery",
title = "New in silico and conventional in vitro approaches to advance HIV drug discovery and design",
volume = "8",
number = "1",
pages = "83-92",
doi = "10.1517/17460441.2013.741118"
}

Maga, G., Veljković, N. V., Crespan, E., Spadari, S., Prljić, J., Perović, V. R., Glišić, S.,& Veljković, V.. (2013). New in silico and conventional in vitro approaches to advance HIV drug discovery and design. in Expert Opinion on Drug Discovery, 8(1), 83-92.
https://doi.org/10.1517/17460441.2013.741118

Maga G, Veljković NV, Crespan E, Spadari S, Prljić J, Perović VR, Glišić S, Veljković V. New in silico and conventional in vitro approaches to advance HIV drug discovery and design. in Expert Opinion on Drug Discovery. 2013;8(1):83-92.
doi:10.1517/17460441.2013.741118 .

Maga, Giovanni, Veljković, Nevena V., Crespan, Emmanuele, Spadari, Silvio, Prljić, Jelena, Perović, Vladimir R., Glišić, Sanja, Veljković, Veljko, "New in silico and conventional in vitro approaches to advance HIV drug discovery and design" in Expert Opinion on Drug Discovery, 8, no. 1 (2013):83-92,
https://doi.org/10.1517/17460441.2013.741118 . .

TY  - JOUR
AU  - Veljković, Nevena V.
AU  - Glišić, Sanja
AU  - Prljić, Jelena
AU  - Perović, Vladimir R.
AU  - Veljković, Veljko
PY  - 2013
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/5758
AB  - Highly active antiretroviral therapy (HAART) dramatically has changed the course of HIV infection. Currently, this therapy involves the use of agents from at least two distinct classes of antivirals: a protease inhibitor in combination with two nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTIs), or a non-nucleoside reverse transcriptase inhibitor (NNRTI) in combination with NRTIs. Recently, the third family of antivirals started to be used clinically, with the advent of enfuvirtide, the first fusion inhibitor. This broad spectrum of anti-HIV agents recently was extended with compounds inhibiting HIV integrase and vital entry. But these advances did not come without a cost: there were the short-and long-term drug toxicities, emergence of drug resistance, and persistence of viral reservoirs. For these reasons, there is a pressing need for novel anti-HIV drugs, particularly those that have a novel action mechanism, as these might be less likely to show cross-resistance with current therapies. The field of bioinformatics has become a major part of the drug discovery pipeline playing a key role in improvement and acceleration of the time and money consuming process of the drug development. Here we review the application of the EIIP/AQVN (Electron-Ion Interaction Potential, EIIP; Average Quasi Valence Number, AQVN) bioinformatics concept in the development of new anti-HIV drugs and propose a simple theoretical criterion for a virtual screening of molecular libraries for promising lead anti-HIV compounds and refinement of selected lead compounds in order to increase their biological activity.
T2  - Current Pharmaceutical Biotechnology
T1  - Simple and General Criterion for in silico Screening of Candidate HIV Drugs
VL  - 14
IS  - 5
SP  - 561
EP  - 569
DO  - 10.2174/138920101405131111105301
ER  - 

@article{
author = "Veljković, Nevena V. and Glišić, Sanja and Prljić, Jelena and Perović, Vladimir R. and Veljković, Veljko",
year = "2013",
abstract = "Highly active antiretroviral therapy (HAART) dramatically has changed the course of HIV infection. Currently, this therapy involves the use of agents from at least two distinct classes of antivirals: a protease inhibitor in combination with two nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTIs), or a non-nucleoside reverse transcriptase inhibitor (NNRTI) in combination with NRTIs. Recently, the third family of antivirals started to be used clinically, with the advent of enfuvirtide, the first fusion inhibitor. This broad spectrum of anti-HIV agents recently was extended with compounds inhibiting HIV integrase and vital entry. But these advances did not come without a cost: there were the short-and long-term drug toxicities, emergence of drug resistance, and persistence of viral reservoirs. For these reasons, there is a pressing need for novel anti-HIV drugs, particularly those that have a novel action mechanism, as these might be less likely to show cross-resistance with current therapies. The field of bioinformatics has become a major part of the drug discovery pipeline playing a key role in improvement and acceleration of the time and money consuming process of the drug development. Here we review the application of the EIIP/AQVN (Electron-Ion Interaction Potential, EIIP; Average Quasi Valence Number, AQVN) bioinformatics concept in the development of new anti-HIV drugs and propose a simple theoretical criterion for a virtual screening of molecular libraries for promising lead anti-HIV compounds and refinement of selected lead compounds in order to increase their biological activity.",
journal = "Current Pharmaceutical Biotechnology",
title = "Simple and General Criterion for in silico Screening of Candidate HIV Drugs",
volume = "14",
number = "5",
pages = "561-569",
doi = "10.2174/138920101405131111105301"
}

Veljković, N. V., Glišić, S., Prljić, J., Perović, V. R.,& Veljković, V.. (2013). Simple and General Criterion for in silico Screening of Candidate HIV Drugs. in Current Pharmaceutical Biotechnology, 14(5), 561-569.
https://doi.org/10.2174/138920101405131111105301

Veljković NV, Glišić S, Prljić J, Perović VR, Veljković V. Simple and General Criterion for in silico Screening of Candidate HIV Drugs. in Current Pharmaceutical Biotechnology. 2013;14(5):561-569.
doi:10.2174/138920101405131111105301 .

Veljković, Nevena V., Glišić, Sanja, Prljić, Jelena, Perović, Vladimir R., Veljković, Veljko, "Simple and General Criterion for in silico Screening of Candidate HIV Drugs" in Current Pharmaceutical Biotechnology, 14, no. 5 (2013):561-569,
https://doi.org/10.2174/138920101405131111105301 . .

TY  - JOUR
AU  - Glišić, Sanja
AU  - Veljković, Nevena V.
AU  - Jovanović-Ćupić, Snežana P.
AU  - Vasiljevic, Nada
AU  - Prljić, Jelena
AU  - Gemović, Branislava S.
AU  - Perović, Vladimir R.
AU  - Veljković, Veljko
PY  - 2012
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/4755
AB  - Hepatitis C virus (HCV) infection is a major and rising global health problem, affecting about 170 million people worldwide. The current standard of care treatment with interferon alpha and ribavirin in patients with the genotype 1 infection, the most frequent genotype in the USA and Western Europe, leads to a successful outcome in only about 50% of individuals. Accurate prediction of hepatitis C treatment response is of great benefit to patients and clinicians. The informational spectrum method, a virtual spectroscopy method for structure/function analysis of nucleotide and protein sequences, is applied here for the identification of the conserved information of the HCV proteins that correlate with the combination therapy outcome. Among the HCV proteins that we have analyzed the informational property of the p7 of HCV genotype 1b was best related to the therapy outcome. On the basis of these results, a simple bioinformatics criterion that could be useful in assessment of the response of HCV-infected patients to the combination therapy has been proposed.
T2  - Protein Journal
T1  - Assessment of Hepatitis C Virus Protein Sequences with Regard to Interferon/Ribavirin Combination Therapy Response in Patients with HCV Genotype 1b
VL  - 31
IS  - 2
SP  - 129
EP  - 136
DO  - 10.1007/s10930-011-9381-6
ER  - 

@article{
author = "Glišić, Sanja and Veljković, Nevena V. and Jovanović-Ćupić, Snežana P. and Vasiljevic, Nada and Prljić, Jelena and Gemović, Branislava S. and Perović, Vladimir R. and Veljković, Veljko",
year = "2012",
abstract = "Hepatitis C virus (HCV) infection is a major and rising global health problem, affecting about 170 million people worldwide. The current standard of care treatment with interferon alpha and ribavirin in patients with the genotype 1 infection, the most frequent genotype in the USA and Western Europe, leads to a successful outcome in only about 50% of individuals. Accurate prediction of hepatitis C treatment response is of great benefit to patients and clinicians. The informational spectrum method, a virtual spectroscopy method for structure/function analysis of nucleotide and protein sequences, is applied here for the identification of the conserved information of the HCV proteins that correlate with the combination therapy outcome. Among the HCV proteins that we have analyzed the informational property of the p7 of HCV genotype 1b was best related to the therapy outcome. On the basis of these results, a simple bioinformatics criterion that could be useful in assessment of the response of HCV-infected patients to the combination therapy has been proposed.",
journal = "Protein Journal",
title = "Assessment of Hepatitis C Virus Protein Sequences with Regard to Interferon/Ribavirin Combination Therapy Response in Patients with HCV Genotype 1b",
volume = "31",
number = "2",
pages = "129-136",
doi = "10.1007/s10930-011-9381-6"
}

Glišić, S., Veljković, N. V., Jovanović-Ćupić, S. P., Vasiljevic, N., Prljić, J., Gemović, B. S., Perović, V. R.,& Veljković, V.. (2012). Assessment of Hepatitis C Virus Protein Sequences with Regard to Interferon/Ribavirin Combination Therapy Response in Patients with HCV Genotype 1b. in Protein Journal, 31(2), 129-136.
https://doi.org/10.1007/s10930-011-9381-6

Glišić S, Veljković NV, Jovanović-Ćupić SP, Vasiljevic N, Prljić J, Gemović BS, Perović VR, Veljković V. Assessment of Hepatitis C Virus Protein Sequences with Regard to Interferon/Ribavirin Combination Therapy Response in Patients with HCV Genotype 1b. in Protein Journal. 2012;31(2):129-136.
doi:10.1007/s10930-011-9381-6 .

Glišić, Sanja, Veljković, Nevena V., Jovanović-Ćupić, Snežana P., Vasiljevic, Nada, Prljić, Jelena, Gemović, Branislava S., Perović, Vladimir R., Veljković, Veljko, "Assessment of Hepatitis C Virus Protein Sequences with Regard to Interferon/Ribavirin Combination Therapy Response in Patients with HCV Genotype 1b" in Protein Journal, 31, no. 2 (2012):129-136,
https://doi.org/10.1007/s10930-011-9381-6 . .

TY  - JOUR
AU  - Vasiljevic, Nada
AU  - Veljković, Nevena V.
AU  - Kosec, Tatjana
AU  - Ma, Xue-Zhong
AU  - Glišić, Sanja
AU  - Prljić, Jelena
AU  - Vujicic, Ana Djordjevic
AU  - Markovic, Ljiljana
AU  - Branch, Donald R.
PY  - 2011
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/4259
AB  - Natural autoantibodies (NAbs) are continually produced throughout life and have an ability to recognize self and altered self, as well as foreign antigens, by recognizing cellular pattern recognition receptors. Sometimes NAb specificity demonstrates overlap between human and pathologic proteomes. This information can be useful in selecting target sequences for screening purposes. In this study we undertook a multi-step bioinformatics search to predict a virus-derived peptide that can be recognized by NAbs in sera of uninfected individuals. We selected protein hepatitis C virus (HCV) NS5A as a target sequence, motivated by the fact that the HCV proteome is characterized by extensive sequence similarities to the human proteome, and because screening for anti-HCV antibodies, including anti-NS5A, is important clinically, particularly in screening of potential blood donors. The virus-specific peptide P1, and the homologous human peptide derived from enzyme-inducible nitric oxide synthase (iNOS), P2, exhibiting not only simple homology, but also complementarities of physicochemical patterns, were synthesized and 80 HCV-negative and 50 HCV-positive blood donor sera were tested by ELISA. These peptides reacted similarly (p LT 0.001) with HCV-negative sera, and in several cases the measured reactivity was significantly above the cut-off value of commercial anti-HCV screening assays. In HCV-positive sera, the titers of antibodies reactive with analyzed HCV NS5A peptide were not significantly increased (p LT 0.001) compared to host peptide, the implications of which are unclear, but may be consistent with these antibodies being naturally produced. Finally, we extended our bioinformatics analyses to the dataset of human self-binding sequences, and propose a general approach for the selection of specific diagnostic and screening antigens for use in immunoassays.
T2  - Viral Immunology
T1  - A Bioinformatics Approach to Identify Natural Autoantibodies from Healthy Blood Donors Sera Reactive with the HCV NS5A-Derived Peptide by Immunoassay
VL  - 24
IS  - 2
SP  - 69
EP  - 76
DO  - 10.1089/vim.2010.0107
ER  - 

@article{
author = "Vasiljevic, Nada and Veljković, Nevena V. and Kosec, Tatjana and Ma, Xue-Zhong and Glišić, Sanja and Prljić, Jelena and Vujicic, Ana Djordjevic and Markovic, Ljiljana and Branch, Donald R.",
year = "2011",
abstract = "Natural autoantibodies (NAbs) are continually produced throughout life and have an ability to recognize self and altered self, as well as foreign antigens, by recognizing cellular pattern recognition receptors. Sometimes NAb specificity demonstrates overlap between human and pathologic proteomes. This information can be useful in selecting target sequences for screening purposes. In this study we undertook a multi-step bioinformatics search to predict a virus-derived peptide that can be recognized by NAbs in sera of uninfected individuals. We selected protein hepatitis C virus (HCV) NS5A as a target sequence, motivated by the fact that the HCV proteome is characterized by extensive sequence similarities to the human proteome, and because screening for anti-HCV antibodies, including anti-NS5A, is important clinically, particularly in screening of potential blood donors. The virus-specific peptide P1, and the homologous human peptide derived from enzyme-inducible nitric oxide synthase (iNOS), P2, exhibiting not only simple homology, but also complementarities of physicochemical patterns, were synthesized and 80 HCV-negative and 50 HCV-positive blood donor sera were tested by ELISA. These peptides reacted similarly (p LT 0.001) with HCV-negative sera, and in several cases the measured reactivity was significantly above the cut-off value of commercial anti-HCV screening assays. In HCV-positive sera, the titers of antibodies reactive with analyzed HCV NS5A peptide were not significantly increased (p LT 0.001) compared to host peptide, the implications of which are unclear, but may be consistent with these antibodies being naturally produced. Finally, we extended our bioinformatics analyses to the dataset of human self-binding sequences, and propose a general approach for the selection of specific diagnostic and screening antigens for use in immunoassays.",
journal = "Viral Immunology",
title = "A Bioinformatics Approach to Identify Natural Autoantibodies from Healthy Blood Donors Sera Reactive with the HCV NS5A-Derived Peptide by Immunoassay",
volume = "24",
number = "2",
pages = "69-76",
doi = "10.1089/vim.2010.0107"
}

Vasiljevic, N., Veljković, N. V., Kosec, T., Ma, X., Glišić, S., Prljić, J., Vujicic, A. D., Markovic, L.,& Branch, D. R.. (2011). A Bioinformatics Approach to Identify Natural Autoantibodies from Healthy Blood Donors Sera Reactive with the HCV NS5A-Derived Peptide by Immunoassay. in Viral Immunology, 24(2), 69-76.
https://doi.org/10.1089/vim.2010.0107

Vasiljevic N, Veljković NV, Kosec T, Ma X, Glišić S, Prljić J, Vujicic AD, Markovic L, Branch DR. A Bioinformatics Approach to Identify Natural Autoantibodies from Healthy Blood Donors Sera Reactive with the HCV NS5A-Derived Peptide by Immunoassay. in Viral Immunology. 2011;24(2):69-76.
doi:10.1089/vim.2010.0107 .

Vasiljevic, Nada, Veljković, Nevena V., Kosec, Tatjana, Ma, Xue-Zhong, Glišić, Sanja, Prljić, Jelena, Vujicic, Ana Djordjevic, Markovic, Ljiljana, Branch, Donald R., "A Bioinformatics Approach to Identify Natural Autoantibodies from Healthy Blood Donors Sera Reactive with the HCV NS5A-Derived Peptide by Immunoassay" in Viral Immunology, 24, no. 2 (2011):69-76,
https://doi.org/10.1089/vim.2010.0107 . .

TY  - JOUR
AU  - Glišić, Sanja
AU  - Arrigo, Patrizio
AU  - Alavantić, Dragan
AU  - Perović, Vladimir R.
AU  - Prljić, Jelena
AU  - Veljković, Nevena V.
PY  - 2008
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/3356
AB  - Lipoprotein lipase (LPL) is a key enzyme in lipid metabolism. Decrease of the LPL enzymatic activity leads to elevated triglycerides (TG) and reduced high-density lipoprotein (HDL-C levels), both risk factors for cardiovascular disease (CVD). Therefore, mutations, which decrease the LPL activity, may confer susceptibility to CVD. Here, the informational spectrum method (ISM), a virtual spectroscopy method for structure/function analysis of nucleotide and protein sequences, is applied for identification of evolutionary highly conserved information encoded by the primary structure of LPL. It was demonstrated that mutations, which alter the LPL enzymatic activity also alter this information. On the basis of this finding, an efficient an simple bioinformatics criterion for assessment of the pathogenic effect of LPL nonsynonymous single nucleotide substitution as a risk factor of CVD has been proposed.
T2  - Proteins: Structure Function and Bioinformatics
T1  - Lipoprotein lipase: A bioinformatics criterion for assessment of mutations as a risk factor for cardiovascular disease
VL  - 70
IS  - 3
SP  - 855
EP  - 862
DO  - 10.1002/prot.21581
ER  - 

@article{
author = "Glišić, Sanja and Arrigo, Patrizio and Alavantić, Dragan and Perović, Vladimir R. and Prljić, Jelena and Veljković, Nevena V.",
year = "2008",
abstract = "Lipoprotein lipase (LPL) is a key enzyme in lipid metabolism. Decrease of the LPL enzymatic activity leads to elevated triglycerides (TG) and reduced high-density lipoprotein (HDL-C levels), both risk factors for cardiovascular disease (CVD). Therefore, mutations, which decrease the LPL activity, may confer susceptibility to CVD. Here, the informational spectrum method (ISM), a virtual spectroscopy method for structure/function analysis of nucleotide and protein sequences, is applied for identification of evolutionary highly conserved information encoded by the primary structure of LPL. It was demonstrated that mutations, which alter the LPL enzymatic activity also alter this information. On the basis of this finding, an efficient an simple bioinformatics criterion for assessment of the pathogenic effect of LPL nonsynonymous single nucleotide substitution as a risk factor of CVD has been proposed.",
journal = "Proteins: Structure Function and Bioinformatics",
title = "Lipoprotein lipase: A bioinformatics criterion for assessment of mutations as a risk factor for cardiovascular disease",
volume = "70",
number = "3",
pages = "855-862",
doi = "10.1002/prot.21581"
}

Glišić, S., Arrigo, P., Alavantić, D., Perović, V. R., Prljić, J.,& Veljković, N. V.. (2008). Lipoprotein lipase: A bioinformatics criterion for assessment of mutations as a risk factor for cardiovascular disease. in Proteins: Structure Function and Bioinformatics, 70(3), 855-862.
https://doi.org/10.1002/prot.21581

Glišić S, Arrigo P, Alavantić D, Perović VR, Prljić J, Veljković NV. Lipoprotein lipase: A bioinformatics criterion for assessment of mutations as a risk factor for cardiovascular disease. in Proteins: Structure Function and Bioinformatics. 2008;70(3):855-862.
doi:10.1002/prot.21581 .

Glišić, Sanja, Arrigo, Patrizio, Alavantić, Dragan, Perović, Vladimir R., Prljić, Jelena, Veljković, Nevena V., "Lipoprotein lipase: A bioinformatics criterion for assessment of mutations as a risk factor for cardiovascular disease" in Proteins: Structure Function and Bioinformatics, 70, no. 3 (2008):855-862,
https://doi.org/10.1002/prot.21581 . .

TY  - JOUR
AU  - Veljković, Nevena V.
AU  - Glišić, Sanja
AU  - Prljić, Jelena
AU  - Perović, Vladimir R.
AU  - Botta, Maurizio
AU  - Veljković, Veljko
PY  - 2008
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/3544
AB  - The field of bioinformatics has become a major part of the drug discovery pipeline playing a key role in improvement and acceleration of this time and money consuming process. Here we review the application of the informational spectrum method ( ISM), a virtual spectroscopy method for structure/function analysis of proteins, in identification of functional protein domains representing candidate therapeutic targets for drugs against human immunodeficiency virus (HIV)-1, anthrax, highly pathogenic influenza virus H5N1 and cardiovascular diseases.
T2  - Current Protein and Peptide Science
T1  - Discovery of New Therapeutic Targets by the Informational Spectrum Method
VL  - 9
IS  - 5
SP  - 493
EP  - 506
DO  - 10.2174/138920308785915245
ER  - 

@article{
author = "Veljković, Nevena V. and Glišić, Sanja and Prljić, Jelena and Perović, Vladimir R. and Botta, Maurizio and Veljković, Veljko",
year = "2008",
abstract = "The field of bioinformatics has become a major part of the drug discovery pipeline playing a key role in improvement and acceleration of this time and money consuming process. Here we review the application of the informational spectrum method ( ISM), a virtual spectroscopy method for structure/function analysis of proteins, in identification of functional protein domains representing candidate therapeutic targets for drugs against human immunodeficiency virus (HIV)-1, anthrax, highly pathogenic influenza virus H5N1 and cardiovascular diseases.",
journal = "Current Protein and Peptide Science",
title = "Discovery of New Therapeutic Targets by the Informational Spectrum Method",
volume = "9",
number = "5",
pages = "493-506",
doi = "10.2174/138920308785915245"
}

Veljković, N. V., Glišić, S., Prljić, J., Perović, V. R., Botta, M.,& Veljković, V.. (2008). Discovery of New Therapeutic Targets by the Informational Spectrum Method. in Current Protein and Peptide Science, 9(5), 493-506.
https://doi.org/10.2174/138920308785915245

Veljković NV, Glišić S, Prljić J, Perović VR, Botta M, Veljković V. Discovery of New Therapeutic Targets by the Informational Spectrum Method. in Current Protein and Peptide Science. 2008;9(5):493-506.
doi:10.2174/138920308785915245 .

Veljković, Nevena V., Glišić, Sanja, Prljić, Jelena, Perović, Vladimir R., Botta, Maurizio, Veljković, Veljko, "Discovery of New Therapeutic Targets by the Informational Spectrum Method" in Current Protein and Peptide Science, 9, no. 5 (2008):493-506,
https://doi.org/10.2174/138920308785915245 . .

TY  - JOUR
AU  - Doliana, Roberto
AU  - Veljković, Veljko
AU  - Prljić, Jelena
AU  - Veljković, Nevena V.
AU  - De Lorenzo, Elisa
AU  - Mongiat, Maurizio
AU  - Ligresti, Giovanni
AU  - Marastoni, Stefano
AU  - Colombatti, Alfonso
PY  - 2008
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/3377
AB  - The informational spectrum method (ISM) is a virtual spectroscopy method for the fast analysis of potential protein-protein relationships. By applying the ISM approach to the GeneBank protein database the vascular proteins EMILIN1 (Elastin Microfibril Interface Located ProteIN), EMILIN2, MMN1, and MMN2 were identified as additional anthrax PA antigen interacting molecules. This virtual molecular interaction was formally proven by solid phase assays using recombinant proteins. The interaction is independent of the presence of divalent cations and does not involve PA aspartic residue at 683, a critical residue in receptor binding. In fact, the D683A point mutation fully prevented the cell intoxication ability of PA in the presence of Lethal Factor, but it was fully ineffective on the binding of mutated PA to EMILIN1 and EMILIN2. The ISM approach also led to the identification of the potential interaction sites between PA and EMILINs. A PA mutant with a deletion at residue D425 and solid phase protein-protein interaction studies as well as deletion mutant of EMILIN2 confirmed the hypothesized interaction site. Our findings imply that the PA-cell surface receptor interaction is not likely to provide the full explanation for the vascular lesions and prominent hemorrhages that follow Bacillus anthracis infection and spreading and call into play vascular associated proteins such as EMILINs as potential inhibitory proteins. (c) 2007 Elsevier B.V/International Society of Matrix Biology. All rights reserved.
T2  - Matrix Biology
T1  - EMILINs Interact with Anthrax Protective Antigen and Inhibit Toxin Action in Vitro
VL  - 27
IS  - 2
SP  - 96
EP  - 106
DO  - 10.1016/j.matbio.2007.09.008
ER  - 

@article{
author = "Doliana, Roberto and Veljković, Veljko and Prljić, Jelena and Veljković, Nevena V. and De Lorenzo, Elisa and Mongiat, Maurizio and Ligresti, Giovanni and Marastoni, Stefano and Colombatti, Alfonso",
year = "2008",
abstract = "The informational spectrum method (ISM) is a virtual spectroscopy method for the fast analysis of potential protein-protein relationships. By applying the ISM approach to the GeneBank protein database the vascular proteins EMILIN1 (Elastin Microfibril Interface Located ProteIN), EMILIN2, MMN1, and MMN2 were identified as additional anthrax PA antigen interacting molecules. This virtual molecular interaction was formally proven by solid phase assays using recombinant proteins. The interaction is independent of the presence of divalent cations and does not involve PA aspartic residue at 683, a critical residue in receptor binding. In fact, the D683A point mutation fully prevented the cell intoxication ability of PA in the presence of Lethal Factor, but it was fully ineffective on the binding of mutated PA to EMILIN1 and EMILIN2. The ISM approach also led to the identification of the potential interaction sites between PA and EMILINs. A PA mutant with a deletion at residue D425 and solid phase protein-protein interaction studies as well as deletion mutant of EMILIN2 confirmed the hypothesized interaction site. Our findings imply that the PA-cell surface receptor interaction is not likely to provide the full explanation for the vascular lesions and prominent hemorrhages that follow Bacillus anthracis infection and spreading and call into play vascular associated proteins such as EMILINs as potential inhibitory proteins. (c) 2007 Elsevier B.V/International Society of Matrix Biology. All rights reserved.",
journal = "Matrix Biology",
title = "EMILINs Interact with Anthrax Protective Antigen and Inhibit Toxin Action in Vitro",
volume = "27",
number = "2",
pages = "96-106",
doi = "10.1016/j.matbio.2007.09.008"
}

Doliana, R., Veljković, V., Prljić, J., Veljković, N. V., De Lorenzo, E., Mongiat, M., Ligresti, G., Marastoni, S.,& Colombatti, A.. (2008). EMILINs Interact with Anthrax Protective Antigen and Inhibit Toxin Action in Vitro. in Matrix Biology, 27(2), 96-106.
https://doi.org/10.1016/j.matbio.2007.09.008

Doliana R, Veljković V, Prljić J, Veljković NV, De Lorenzo E, Mongiat M, Ligresti G, Marastoni S, Colombatti A. EMILINs Interact with Anthrax Protective Antigen and Inhibit Toxin Action in Vitro. in Matrix Biology. 2008;27(2):96-106.
doi:10.1016/j.matbio.2007.09.008 .

Doliana, Roberto, Veljković, Veljko, Prljić, Jelena, Veljković, Nevena V., De Lorenzo, Elisa, Mongiat, Maurizio, Ligresti, Giovanni, Marastoni, Stefano, Colombatti, Alfonso, "EMILINs Interact with Anthrax Protective Antigen and Inhibit Toxin Action in Vitro" in Matrix Biology, 27, no. 2 (2008):96-106,
https://doi.org/10.1016/j.matbio.2007.09.008 . .

TY  - JOUR
AU  - Veljković, Veljko
AU  - Prljić, Jelena
AU  - Veljković, Tatjana
PY  - 2004
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2809
AB  - It has been demonstrated that HIV-1 gp120 resembles several important properties of immunoglobulins allowing it strong influence on the human immune system, especially through induction of the deceptive imprinting and deregulation of the immune network. On the other hand there are many unanswered questions concerning properties and control of the genetically modified viruses and bacteria used as vectors in AIDS vaccines. This situation opens a serious question about the safety of vectored AIDS vaccine and the ethics of their trials in humans.
T2  - International Reviews of Immunology
T1  - Safety and ethical consideration of AIDS vaccine
VL  - 23
IS  - 5-6
SP  - 465
EP  - 486
DO  - 10.1080/08830180490432866
ER  - 

@article{
author = "Veljković, Veljko and Prljić, Jelena and Veljković, Tatjana",
year = "2004",
abstract = "It has been demonstrated that HIV-1 gp120 resembles several important properties of immunoglobulins allowing it strong influence on the human immune system, especially through induction of the deceptive imprinting and deregulation of the immune network. On the other hand there are many unanswered questions concerning properties and control of the genetically modified viruses and bacteria used as vectors in AIDS vaccines. This situation opens a serious question about the safety of vectored AIDS vaccine and the ethics of their trials in humans.",
journal = "International Reviews of Immunology",
title = "Safety and ethical consideration of AIDS vaccine",
volume = "23",
number = "5-6",
pages = "465-486",
doi = "10.1080/08830180490432866"
}

Veljković, V., Prljić, J.,& Veljković, T.. (2004). Safety and ethical consideration of AIDS vaccine. in International Reviews of Immunology, 23(5-6), 465-486.
https://doi.org/10.1080/08830180490432866

Veljković V, Prljić J, Veljković T. Safety and ethical consideration of AIDS vaccine. in International Reviews of Immunology. 2004;23(5-6):465-486.
doi:10.1080/08830180490432866 .

Veljković, Veljko, Prljić, Jelena, Veljković, Tatjana, "Safety and ethical consideration of AIDS vaccine" in International Reviews of Immunology, 23, no. 5-6 (2004):465-486,
https://doi.org/10.1080/08830180490432866 . .

TY  - JOUR
AU  - Prljić, Jelena
AU  - Veljković, Nevena V.
AU  - Veljković, Veljko
PY  - 2004
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2808
AB  - Using a chimeric primer consisting of the nucleotide sequence derived from the HIV-1 envelope gene coding for the second conserved region of gp120, and the highly conserved sequence derived from the human immunoglobulin gene coding for the VHIII domain, it has been identified in sera of AIDS patients HIV-1 field isolates carrying the complete and active Chi recombination hot spot (GCTGGTGG). The recombination between the HIV-1 gene coding for the central portion of gp120 and the bacterial gene coding for the clp protease was also demonstrated in vivo. These results point out serious concern that vectored AIDS vaccine candidates carrying the HIV-1 env gene on viral and bacterial vectors could become the source of potentially new infectious diseases rather than an effective instrument for AIDS prevention.
T2  - International Reviews of Immunology
T1  - Recombination property of the HIV-1 gp120 gene
VL  - 23
IS  - 5-6
SP  - 447
EP  - 454
DO  - 10.1080/08830180490432839
ER  - 

@article{
author = "Prljić, Jelena and Veljković, Nevena V. and Veljković, Veljko",
year = "2004",
abstract = "Using a chimeric primer consisting of the nucleotide sequence derived from the HIV-1 envelope gene coding for the second conserved region of gp120, and the highly conserved sequence derived from the human immunoglobulin gene coding for the VHIII domain, it has been identified in sera of AIDS patients HIV-1 field isolates carrying the complete and active Chi recombination hot spot (GCTGGTGG). The recombination between the HIV-1 gene coding for the central portion of gp120 and the bacterial gene coding for the clp protease was also demonstrated in vivo. These results point out serious concern that vectored AIDS vaccine candidates carrying the HIV-1 env gene on viral and bacterial vectors could become the source of potentially new infectious diseases rather than an effective instrument for AIDS prevention.",
journal = "International Reviews of Immunology",
title = "Recombination property of the HIV-1 gp120 gene",
volume = "23",
number = "5-6",
pages = "447-454",
doi = "10.1080/08830180490432839"
}

Prljić, J., Veljković, N. V.,& Veljković, V.. (2004). Recombination property of the HIV-1 gp120 gene. in International Reviews of Immunology, 23(5-6), 447-454.
https://doi.org/10.1080/08830180490432839

Prljić J, Veljković NV, Veljković V. Recombination property of the HIV-1 gp120 gene. in International Reviews of Immunology. 2004;23(5-6):447-454.
doi:10.1080/08830180490432839 .

Prljić, Jelena, Veljković, Nevena V., Veljković, Veljko, "Recombination property of the HIV-1 gp120 gene" in International Reviews of Immunology, 23, no. 5-6 (2004):447-454,
https://doi.org/10.1080/08830180490432839 . .

TY  - JOUR
AU  - Ivanović, Vesna
AU  - Demajo, Miroslav
AU  - Todorović-Raković, N
AU  - Nikolić-Vukosavljević, Dragica
AU  - Nešković-Konstantinović, Zora
AU  - Krtolica-Žikić, Koviljka
AU  - Veljković, Veljko
AU  - Prljić, Jelena
AU  - Dimitrijević, Bogomir B.
PY  - 2004
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2769
AB  - Although overexpression of TGF-beta(1) protein has been demonstrated in advanced breast cancer(BC) patients, as well as in other solid tumours, the molecular mechanism of this process remains obscure. This paper proposes that a genetic/epigenetic alteration might occur in the TGF-beta(1) gene, within the region coding for the recognition site with TGF(beta) receptor type II, leading to a disruption of the ligand-receptor interaction and triggering the TGF-beta(1) cascade-related BC progression. To establish the operational framework for this hypothesis, in the present study, this recognition site was identified by the Informational Spectrum Method (ISM) to comprise two TGF-beta(1) peptides (positions 47-66 as and 83-112 aa) and one receptor peptide at positions 112-151 as of the extracellular domain of the receptor (TbetaRII(M)). The TbetaRII(M) locus was further evaluated by ISM-derived deletion analysis of the TbetaRII sequences. To provide experimental support for the proposed model, a pilot study of plasma TGF-beta(1) analysis was performed in advanced BC patients (n = 8). Two commercial ELISA assays, one with specific alphaTGF-beta(1) MAb (MAb) and other with TbetaRII(M) as the immobilized phase, revealed pronounced differences in the pattern of plasma TGF-beta(1) elevation. In MAb-profile, the TGF-beta(1) increase was detected in 7 of 8 patients, whereas analogous TbetaRII(M)-profile revealed the elevation in 3 of 8 patients, taking a 50% of maximal elevation as the cut-off value. These findings are consistent with the proposed aberration of TGF-beta(1) ligand within the TbetaRII recognition site. Summarizing, this model system is a good starting point for further genetic studies, particularly on genetic/epigenetic alterations of sequences involved in TGF-beta(1) and TbetaRII(M) interaction, with putative prognostic value for breast cancer. (C) 2004 Elsevier Ltd. All rights reserved.
T2  - Medical Hypotheses
T1  - Localization of recognition site between transforming growth factor-beta(1) (TGF-beta(1)) and TGF beta receptor type II: possible implications in breast cancer
VL  - 62
IS  - 5
SP  - 727
EP  - 732
DO  - 10.1016/j.mehy.2003.11.027
ER  - 

@article{
author = "Ivanović, Vesna and Demajo, Miroslav and Todorović-Raković, N and Nikolić-Vukosavljević, Dragica and Nešković-Konstantinović, Zora and Krtolica-Žikić, Koviljka and Veljković, Veljko and Prljić, Jelena and Dimitrijević, Bogomir B.",
year = "2004",
abstract = "Although overexpression of TGF-beta(1) protein has been demonstrated in advanced breast cancer(BC) patients, as well as in other solid tumours, the molecular mechanism of this process remains obscure. This paper proposes that a genetic/epigenetic alteration might occur in the TGF-beta(1) gene, within the region coding for the recognition site with TGF(beta) receptor type II, leading to a disruption of the ligand-receptor interaction and triggering the TGF-beta(1) cascade-related BC progression. To establish the operational framework for this hypothesis, in the present study, this recognition site was identified by the Informational Spectrum Method (ISM) to comprise two TGF-beta(1) peptides (positions 47-66 as and 83-112 aa) and one receptor peptide at positions 112-151 as of the extracellular domain of the receptor (TbetaRII(M)). The TbetaRII(M) locus was further evaluated by ISM-derived deletion analysis of the TbetaRII sequences. To provide experimental support for the proposed model, a pilot study of plasma TGF-beta(1) analysis was performed in advanced BC patients (n = 8). Two commercial ELISA assays, one with specific alphaTGF-beta(1) MAb (MAb) and other with TbetaRII(M) as the immobilized phase, revealed pronounced differences in the pattern of plasma TGF-beta(1) elevation. In MAb-profile, the TGF-beta(1) increase was detected in 7 of 8 patients, whereas analogous TbetaRII(M)-profile revealed the elevation in 3 of 8 patients, taking a 50% of maximal elevation as the cut-off value. These findings are consistent with the proposed aberration of TGF-beta(1) ligand within the TbetaRII recognition site. Summarizing, this model system is a good starting point for further genetic studies, particularly on genetic/epigenetic alterations of sequences involved in TGF-beta(1) and TbetaRII(M) interaction, with putative prognostic value for breast cancer. (C) 2004 Elsevier Ltd. All rights reserved.",
journal = "Medical Hypotheses",
title = "Localization of recognition site between transforming growth factor-beta(1) (TGF-beta(1)) and TGF beta receptor type II: possible implications in breast cancer",
volume = "62",
number = "5",
pages = "727-732",
doi = "10.1016/j.mehy.2003.11.027"
}

Ivanović, V., Demajo, M., Todorović-Raković, N., Nikolić-Vukosavljević, D., Nešković-Konstantinović, Z., Krtolica-Žikić, K., Veljković, V., Prljić, J.,& Dimitrijević, B. B.. (2004). Localization of recognition site between transforming growth factor-beta(1) (TGF-beta(1)) and TGF beta receptor type II: possible implications in breast cancer. in Medical Hypotheses, 62(5), 727-732.
https://doi.org/10.1016/j.mehy.2003.11.027

Ivanović V, Demajo M, Todorović-Raković N, Nikolić-Vukosavljević D, Nešković-Konstantinović Z, Krtolica-Žikić K, Veljković V, Prljić J, Dimitrijević BB. Localization of recognition site between transforming growth factor-beta(1) (TGF-beta(1)) and TGF beta receptor type II: possible implications in breast cancer. in Medical Hypotheses. 2004;62(5):727-732.
doi:10.1016/j.mehy.2003.11.027 .

Ivanović, Vesna, Demajo, Miroslav, Todorović-Raković, N, Nikolić-Vukosavljević, Dragica, Nešković-Konstantinović, Zora, Krtolica-Žikić, Koviljka, Veljković, Veljko, Prljić, Jelena, Dimitrijević, Bogomir B., "Localization of recognition site between transforming growth factor-beta(1) (TGF-beta(1)) and TGF beta receptor type II: possible implications in breast cancer" in Medical Hypotheses, 62, no. 5 (2004):727-732,
https://doi.org/10.1016/j.mehy.2003.11.027 . .

TY  - JOUR
AU  - Veljković, Nevena V.
AU  - Branch, DR
AU  - Metlaš, Radmila
AU  - Prljić, Jelena
AU  - Manfredi, R
AU  - Stringer, WW
AU  - Veljković, Veljko
PY  - 2004
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2837
AB  - It has been reported that antibodies reactive with peptide RSANFTDNAKTIIVQLNQSVEIN (peptide NTM) derived from the C-terminus of the second conserved domain of HIV-1 envelope glycoprotein gp120 could represent an important factor in control of the HIV disease. In order to check this notion we (i) tested reactivity with peptide NTM serum samples collected from 310 consecutive HIV-1 infected patients with a CD4(+) lymphocyte count ranging from 10 to 800/muL and (ii) performed the longitudinal study that included 107 sera samples collected from 29 HIV patients. Results of these studies demonstrated correlation between presence of anti-NTM antibodies in sera of HIV patients and disease progression measured by the CD4(+) cell count. Based on these findings we proposed the anti-NTM antibodies as useful prognostic marker for HIV disease. (C) 2004 Elsevier B.V. All rights reserved.
T2  - Journal of Clinical Virology
T1  - Antibodies reactive with C-terminus of the second conserved region of HIV-1gp120 as possible prognostic marker and therapeutic agent for HIV disease
VL  - 31
SP  - S39
EP  - S44
DO  - 10.1016/j.jcv.2004.09.012
ER  - 

@article{
author = "Veljković, Nevena V. and Branch, DR and Metlaš, Radmila and Prljić, Jelena and Manfredi, R and Stringer, WW and Veljković, Veljko",
year = "2004",
abstract = "It has been reported that antibodies reactive with peptide RSANFTDNAKTIIVQLNQSVEIN (peptide NTM) derived from the C-terminus of the second conserved domain of HIV-1 envelope glycoprotein gp120 could represent an important factor in control of the HIV disease. In order to check this notion we (i) tested reactivity with peptide NTM serum samples collected from 310 consecutive HIV-1 infected patients with a CD4(+) lymphocyte count ranging from 10 to 800/muL and (ii) performed the longitudinal study that included 107 sera samples collected from 29 HIV patients. Results of these studies demonstrated correlation between presence of anti-NTM antibodies in sera of HIV patients and disease progression measured by the CD4(+) cell count. Based on these findings we proposed the anti-NTM antibodies as useful prognostic marker for HIV disease. (C) 2004 Elsevier B.V. All rights reserved.",
journal = "Journal of Clinical Virology",
title = "Antibodies reactive with C-terminus of the second conserved region of HIV-1gp120 as possible prognostic marker and therapeutic agent for HIV disease",
volume = "31",
pages = "S39-S44",
doi = "10.1016/j.jcv.2004.09.012"
}

Veljković, N. V., Branch, D., Metlaš, R., Prljić, J., Manfredi, R., Stringer, W.,& Veljković, V.. (2004). Antibodies reactive with C-terminus of the second conserved region of HIV-1gp120 as possible prognostic marker and therapeutic agent for HIV disease. in Journal of Clinical Virology, 31, S39-S44.
https://doi.org/10.1016/j.jcv.2004.09.012

Veljković NV, Branch D, Metlaš R, Prljić J, Manfredi R, Stringer W, Veljković V. Antibodies reactive with C-terminus of the second conserved region of HIV-1gp120 as possible prognostic marker and therapeutic agent for HIV disease. in Journal of Clinical Virology. 2004;31:S39-S44.
doi:10.1016/j.jcv.2004.09.012 .

Veljković, Nevena V., Branch, DR, Metlaš, Radmila, Prljić, Jelena, Manfredi, R, Stringer, WW, Veljković, Veljko, "Antibodies reactive with C-terminus of the second conserved region of HIV-1gp120 as possible prognostic marker and therapeutic agent for HIV disease" in Journal of Clinical Virology, 31 (2004):S39-S44,
https://doi.org/10.1016/j.jcv.2004.09.012 . .

TY  - JOUR
AU  - Veljković, Nevena V.
AU  - Branch, DR
AU  - Metlaš, Radmila
AU  - Prljić, Jelena
AU  - Vlahovicek, K
AU  - Pongor, S
AU  - Veljković, Veljko
PY  - 2003
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2693
AB  - It has been reported that the C-terminus of the second conserved region (C2) of the envelope glycoprotein gp120, encompassing peptide RSANFTDNAKTIIVQLNESVEIN (NTM), is important for infectivity and neutralization of the human immunodeficiency virus type 1 (HIV-1). It was also demonstrated that human natural anti-vasoactive intestinal peptide (VIP) antibodies reactive with this gp120 region play an important role in control of HIV disease progression. The bioinformatic analysis based on the time-frequency signal processing revealed non-obvious similarities between NTM and VIP. When tested against a battery of sera from 46 AIDS patients, these peptides, in spite of a significant difference in their primary structures, showed a similar reactivity profiles (r = 0.83). Presented results point out that similarity in the periodical pattern of some physicochemical properties in primary structures of peptides plays a significant role in determination of their immunological crossreactivity. Based on these findings, we propose this bioinformatic criterion be used for design of VIP/NTM peptide mimetics for prevention and treatment of HIV disease.
T2  - Journal of Peptide Research
T1  - Design of peptide mimetics of HIV-1 gp120 for prevention and therapy of HIV disease
VL  - 62
IS  - 4
SP  - 158
EP  - 166
DO  - 10.1034/j.1399-3011.2003.00081.x
ER  - 

@article{
author = "Veljković, Nevena V. and Branch, DR and Metlaš, Radmila and Prljić, Jelena and Vlahovicek, K and Pongor, S and Veljković, Veljko",
year = "2003",
abstract = "It has been reported that the C-terminus of the second conserved region (C2) of the envelope glycoprotein gp120, encompassing peptide RSANFTDNAKTIIVQLNESVEIN (NTM), is important for infectivity and neutralization of the human immunodeficiency virus type 1 (HIV-1). It was also demonstrated that human natural anti-vasoactive intestinal peptide (VIP) antibodies reactive with this gp120 region play an important role in control of HIV disease progression. The bioinformatic analysis based on the time-frequency signal processing revealed non-obvious similarities between NTM and VIP. When tested against a battery of sera from 46 AIDS patients, these peptides, in spite of a significant difference in their primary structures, showed a similar reactivity profiles (r = 0.83). Presented results point out that similarity in the periodical pattern of some physicochemical properties in primary structures of peptides plays a significant role in determination of their immunological crossreactivity. Based on these findings, we propose this bioinformatic criterion be used for design of VIP/NTM peptide mimetics for prevention and treatment of HIV disease.",
journal = "Journal of Peptide Research",
title = "Design of peptide mimetics of HIV-1 gp120 for prevention and therapy of HIV disease",
volume = "62",
number = "4",
pages = "158-166",
doi = "10.1034/j.1399-3011.2003.00081.x"
}

Veljković, N. V., Branch, D., Metlaš, R., Prljić, J., Vlahovicek, K., Pongor, S.,& Veljković, V.. (2003). Design of peptide mimetics of HIV-1 gp120 for prevention and therapy of HIV disease. in Journal of Peptide Research, 62(4), 158-166.
https://doi.org/10.1034/j.1399-3011.2003.00081.x

Veljković NV, Branch D, Metlaš R, Prljić J, Vlahovicek K, Pongor S, Veljković V. Design of peptide mimetics of HIV-1 gp120 for prevention and therapy of HIV disease. in Journal of Peptide Research. 2003;62(4):158-166.
doi:10.1034/j.1399-3011.2003.00081.x .

Veljković, Nevena V., Branch, DR, Metlaš, Radmila, Prljić, Jelena, Vlahovicek, K, Pongor, S, Veljković, Veljko, "Design of peptide mimetics of HIV-1 gp120 for prevention and therapy of HIV disease" in Journal of Peptide Research, 62, no. 4 (2003):158-166,
https://doi.org/10.1034/j.1399-3011.2003.00081.x . .

TY  - JOUR
AU  - Veljković, Veljko
AU  - Metlaš, Radmila
AU  - Kohler, Heike
AU  - Urnovitz, HB
AU  - Prljić, Jelena
AU  - Veljković, Nevena V.
AU  - Johnson, Emmett
AU  - Muller, S
PY  - 2001
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2419
AB  - Current expansion of AIDS pandemic significantly accelerates AIDS vaccine research resulting in development and clinical testing of several AIDS vaccine candidates. At the same time, available experimental and clinical data demonstrate that current AIDS vaccine strategy is unsuccessful resulting in development of inefficient and harmful vaccines. This overview briefly summarizes reported results which point out the requirement for moratorium on the current clinical trials of HIV-1 gp120/160 vaccines and urgent need for development of a new, efficient and safe AIDS vaccine strategy. (C) 2001 Elsevier Science Ltd. All rights reserved.
T2  - Vaccine
T1  - AIDS epidemic at the beginning of the third millennium: time for a new AIDS vaccine strategy
VL  - 19
IS  - 15-16
SP  - 1855
EP  - 1862
DO  - 10.1016/S0264-410X(00)00194-8
ER  - 

@article{
author = "Veljković, Veljko and Metlaš, Radmila and Kohler, Heike and Urnovitz, HB and Prljić, Jelena and Veljković, Nevena V. and Johnson, Emmett and Muller, S",
year = "2001",
abstract = "Current expansion of AIDS pandemic significantly accelerates AIDS vaccine research resulting in development and clinical testing of several AIDS vaccine candidates. At the same time, available experimental and clinical data demonstrate that current AIDS vaccine strategy is unsuccessful resulting in development of inefficient and harmful vaccines. This overview briefly summarizes reported results which point out the requirement for moratorium on the current clinical trials of HIV-1 gp120/160 vaccines and urgent need for development of a new, efficient and safe AIDS vaccine strategy. (C) 2001 Elsevier Science Ltd. All rights reserved.",
journal = "Vaccine",
title = "AIDS epidemic at the beginning of the third millennium: time for a new AIDS vaccine strategy",
volume = "19",
number = "15-16",
pages = "1855-1862",
doi = "10.1016/S0264-410X(00)00194-8"
}

Veljković, V., Metlaš, R., Kohler, H., Urnovitz, H., Prljić, J., Veljković, N. V., Johnson, E.,& Muller, S.. (2001). AIDS epidemic at the beginning of the third millennium: time for a new AIDS vaccine strategy. in Vaccine, 19(15-16), 1855-1862.
https://doi.org/10.1016/S0264-410X(00)00194-8

Veljković V, Metlaš R, Kohler H, Urnovitz H, Prljić J, Veljković NV, Johnson E, Muller S. AIDS epidemic at the beginning of the third millennium: time for a new AIDS vaccine strategy. in Vaccine. 2001;19(15-16):1855-1862.
doi:10.1016/S0264-410X(00)00194-8 .

Veljković, Veljko, Metlaš, Radmila, Kohler, Heike, Urnovitz, HB, Prljić, Jelena, Veljković, Nevena V., Johnson, Emmett, Muller, S, "AIDS epidemic at the beginning of the third millennium: time for a new AIDS vaccine strategy" in Vaccine, 19, no. 15-16 (2001):1855-1862,
https://doi.org/10.1016/S0264-410X(00)00194-8 . .

TY  - CONF
AU  - Vasiljevic, NR
AU  - Taseski, JJ
AU  - Prljić, Jelena
AU  - Veljković, Nevena V.
PY  - 2000
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2382
C3  - Transfusion
T1  - Rational for selection of DNA and peptide sequences derived the major envelope protein E2 for development of the HCV diagnostic test kits
VL  - 40
IS  - 10
SP  - 78S
EP  - 78S
UR  - https://hdl.handle.net/21.15107/rcub_vinar_2382
ER  - 

@conference{
author = "Vasiljevic, NR and Taseski, JJ and Prljić, Jelena and Veljković, Nevena V.",
year = "2000",
journal = "Transfusion",
title = "Rational for selection of DNA and peptide sequences derived the major envelope protein E2 for development of the HCV diagnostic test kits",
volume = "40",
number = "10",
pages = "78S-78S",
url = "https://hdl.handle.net/21.15107/rcub_vinar_2382"
}

Vasiljevic, N., Taseski, J., Prljić, J.,& Veljković, N. V.. (2000). Rational for selection of DNA and peptide sequences derived the major envelope protein E2 for development of the HCV diagnostic test kits. in Transfusion, 40(10), 78S-78S.
https://hdl.handle.net/21.15107/rcub_vinar_2382

Vasiljevic N, Taseski J, Prljić J, Veljković NV. Rational for selection of DNA and peptide sequences derived the major envelope protein E2 for development of the HCV diagnostic test kits. in Transfusion. 2000;40(10):78S-78S.
https://hdl.handle.net/21.15107/rcub_vinar_2382 .

Vasiljevic, NR, Taseski, JJ, Prljić, Jelena, Veljković, Nevena V., "Rational for selection of DNA and peptide sequences derived the major envelope protein E2 for development of the HCV diagnostic test kits" in Transfusion, 40, no. 10 (2000):78S-78S,
https://hdl.handle.net/21.15107/rcub_vinar_2382 .

TY  - JOUR
AU  - Prljić, Jelena
AU  - Veljković, Nevena V.
AU  - Doliana, R
AU  - Colombatti, A
AU  - Johnson, Emmett
AU  - Metlaš, Radmila
AU  - Veljković, Veljko
PY  - 1999
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2230
AB  - Because of a sequence similarity between the HIV-1 envelope glycoprotein gp120 and the variable region of human immunoglobulins, we have suggested that the use of this protein as a vaccine component could strongly influence the host immune system, making it more vulnerable to HIV, and in the long term, accelerate disease progression in asymptomatic HIV patients. Using a chimeric primer consisting of the nucleotide sequence derived from the HIV-1 env gene coding for the second conserved region of gp120, and the highly conserved sequence derived from the human immunoglobulin gene coding for the VHIII domain, we have identified in sera of AIDS patients HIV-I field isolates carrying the complete and active Chi recombinational hot spot (GCTGGTGG). We have also demonstrated in vivo recombination between the HIV-I gene coding for the central portion of the gp120 involving the V3 loop and the bacterial gene coding for the clp protease. These results strongly support and reinforce the previous contention and the serious concern that AIDS vaccine candidates carrying the HIV-1 env gene on viral and bacterial vectors, could result in the generation of new pathogens with unpredictable effects on the immune system. (C) 1999 Elsevier Science Ltd. All rights reserved.
T2  - Vaccine
T1  - Identification of an active Chi recombinational hot spot within the HIV-1 envelope gene: consequences for development of AIDS vaccines
VL  - 17
IS  - 11-12
SP  - 1462
EP  - 1467
DO  - 10.1016/S0264-410X(98)00373-9
ER  - 

@article{
author = "Prljić, Jelena and Veljković, Nevena V. and Doliana, R and Colombatti, A and Johnson, Emmett and Metlaš, Radmila and Veljković, Veljko",
year = "1999",
abstract = "Because of a sequence similarity between the HIV-1 envelope glycoprotein gp120 and the variable region of human immunoglobulins, we have suggested that the use of this protein as a vaccine component could strongly influence the host immune system, making it more vulnerable to HIV, and in the long term, accelerate disease progression in asymptomatic HIV patients. Using a chimeric primer consisting of the nucleotide sequence derived from the HIV-1 env gene coding for the second conserved region of gp120, and the highly conserved sequence derived from the human immunoglobulin gene coding for the VHIII domain, we have identified in sera of AIDS patients HIV-I field isolates carrying the complete and active Chi recombinational hot spot (GCTGGTGG). We have also demonstrated in vivo recombination between the HIV-I gene coding for the central portion of the gp120 involving the V3 loop and the bacterial gene coding for the clp protease. These results strongly support and reinforce the previous contention and the serious concern that AIDS vaccine candidates carrying the HIV-1 env gene on viral and bacterial vectors, could result in the generation of new pathogens with unpredictable effects on the immune system. (C) 1999 Elsevier Science Ltd. All rights reserved.",
journal = "Vaccine",
title = "Identification of an active Chi recombinational hot spot within the HIV-1 envelope gene: consequences for development of AIDS vaccines",
volume = "17",
number = "11-12",
pages = "1462-1467",
doi = "10.1016/S0264-410X(98)00373-9"
}

Prljić, J., Veljković, N. V., Doliana, R., Colombatti, A., Johnson, E., Metlaš, R.,& Veljković, V.. (1999). Identification of an active Chi recombinational hot spot within the HIV-1 envelope gene: consequences for development of AIDS vaccines. in Vaccine, 17(11-12), 1462-1467.
https://doi.org/10.1016/S0264-410X(98)00373-9

Prljić J, Veljković NV, Doliana R, Colombatti A, Johnson E, Metlaš R, Veljković V. Identification of an active Chi recombinational hot spot within the HIV-1 envelope gene: consequences for development of AIDS vaccines. in Vaccine. 1999;17(11-12):1462-1467.
doi:10.1016/S0264-410X(98)00373-9 .

Prljić, Jelena, Veljković, Nevena V., Doliana, R, Colombatti, A, Johnson, Emmett, Metlaš, Radmila, Veljković, Veljko, "Identification of an active Chi recombinational hot spot within the HIV-1 envelope gene: consequences for development of AIDS vaccines" in Vaccine, 17, no. 11-12 (1999):1462-1467,
https://doi.org/10.1016/S0264-410X(98)00373-9 . .

TY  - JOUR
AU  - Glišić, Sanja
AU  - Prljić, Jelena
AU  - Radovanovic, N
AU  - Alavantić, Dragan
PY  - 1997
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2076
AB  - The apolipoprotein B (apoB) signal peptide polymorphism was studied in unrelated healthy individuals. A total of 232 women and 222 men were analyzed separately. The relative frequencies of Del allele in women and men were 0.42 and 0.37, respectively. More heterozygous individuals were detected in comparison with other populations, using a modified silver staining method on polyacrylamide gel for visualization of Ins and Del alleles. There was no statistically significant difference in mean lipid levels adjusted for age, BMI, smoking habit and blood pressure between the three Ins/Del genotypes in both samples (ANOVA). Therefore, no differences were shown in the genotype frequency distribution throughout the lipid quartiles. (C) 1997 Elsevier Science B.V.
T2  - Clinica Chimica Acta
T1  - Study of apoB gene signal peptide insertion/deletion polymorphism in a healthy Serbian population: no association with serum lipid levels
VL  - 263
IS  - 1
SP  - 57
EP  - 65
DO  - 10.1016/S0009-8981(97)06556-X
ER  - 

@article{
author = "Glišić, Sanja and Prljić, Jelena and Radovanovic, N and Alavantić, Dragan",
year = "1997",
abstract = "The apolipoprotein B (apoB) signal peptide polymorphism was studied in unrelated healthy individuals. A total of 232 women and 222 men were analyzed separately. The relative frequencies of Del allele in women and men were 0.42 and 0.37, respectively. More heterozygous individuals were detected in comparison with other populations, using a modified silver staining method on polyacrylamide gel for visualization of Ins and Del alleles. There was no statistically significant difference in mean lipid levels adjusted for age, BMI, smoking habit and blood pressure between the three Ins/Del genotypes in both samples (ANOVA). Therefore, no differences were shown in the genotype frequency distribution throughout the lipid quartiles. (C) 1997 Elsevier Science B.V.",
journal = "Clinica Chimica Acta",
title = "Study of apoB gene signal peptide insertion/deletion polymorphism in a healthy Serbian population: no association with serum lipid levels",
volume = "263",
number = "1",
pages = "57-65",
doi = "10.1016/S0009-8981(97)06556-X"
}

Glišić, S., Prljić, J., Radovanovic, N.,& Alavantić, D.. (1997). Study of apoB gene signal peptide insertion/deletion polymorphism in a healthy Serbian population: no association with serum lipid levels. in Clinica Chimica Acta, 263(1), 57-65.
https://doi.org/10.1016/S0009-8981(97)06556-X

Glišić S, Prljić J, Radovanovic N, Alavantić D. Study of apoB gene signal peptide insertion/deletion polymorphism in a healthy Serbian population: no association with serum lipid levels. in Clinica Chimica Acta. 1997;263(1):57-65.
doi:10.1016/S0009-8981(97)06556-X .

Glišić, Sanja, Prljić, Jelena, Radovanovic, N, Alavantić, Dragan, "Study of apoB gene signal peptide insertion/deletion polymorphism in a healthy Serbian population: no association with serum lipid levels" in Clinica Chimica Acta, 263, no. 1 (1997):57-65,
https://doi.org/10.1016/S0009-8981(97)06556-X . .